0.396
-0.01 (-2.80%)
| 前收盘价格 | 0.408 |
| 收盘价格 | 0.418 |
| 成交量 | 20,191 |
| 平均成交量 (3个月) | 4,926,051 |
| 市值 | 2,248,693 |
| 价格/销量 (P/S) | 2.19 |
| 股市价格/股市净资产 (P/B) | 2.25 |
| 52周波幅 | |
| 利润日期 | 26 Mar 2025 - 31 Mar 2025 |
| 营业利益率 (TTM) | -2,044.08% |
| 稀释每股收益 (EPS TTM) | -4.33 |
| 季度收入增长率 (YOY) | 13.40% |
| 总债务/股东权益 (D/E MRQ) | 1.13% |
| 流动比率 (MRQ) | 1.58 |
| 营业现金流 (OCF TTM) | -11.04 M |
| 杠杆自由现金流 (LFCF TTM) | -5.86 M |
| 资产报酬率 (ROA TTM) | -154.25% |
| 股东权益报酬率 (ROE TTM) | -688.88% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Helius Medical Technologies, In | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.17 |
|
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 0.32% |
| 机构持股比例 | 4.04% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Grant Private Wealth Management Inc | 31 Dec 2024 | 37,193 |
| Fedenia Advisers Llc | 31 Dec 2024 | 100 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合